These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 25643257)

  • 1. Atypical PKCι as target for glioblastoma therapy.
    Lorimer IA
    Curr Cancer Drug Targets; 2015; 15(2):136-44. PubMed ID: 25643257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting atypical protein kinase C iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism.
    Phillips E; Lang V; Bohlen J; Bethke F; Puccio L; Tichy D; Herold-Mende C; Hielscher T; Lichter P; Goidts V
    Int J Cancer; 2016 Oct; 139(8):1776-87. PubMed ID: 27299852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase Ciota-mediated attenuation of p38 MAP kinase signaling.
    Baldwin RM; Garratt-Lalonde M; Parolin DA; Krzyzanowski PM; Andrade MA; Lorimer IA
    Oncogene; 2006 May; 25(20):2909-19. PubMed ID: 16331246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coordination of glioblastoma cell motility by PKCι.
    Baldwin RM; Barrett GM; Parolin DA; Gillies JK; Paget JA; Lavictoire SJ; Gray DA; Lorimer IA
    Mol Cancer; 2010 Sep; 9():233. PubMed ID: 20815904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic strategies to target multiple kinases in glioblastoma.
    Sathornsumetee S
    Anticancer Agents Med Chem; 2011 Oct; 11(8):700-11. PubMed ID: 21707500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic Lymphoma Kinase in Glioblastoma: Detection/Diagnostic Methods and Therapeutic Options.
    Kalamatianos T; Denekou D; Stranjalis G; Papadimitriou E
    Recent Pat Anticancer Drug Discov; 2018; 13(2):209-223. PubMed ID: 29336268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the oncogenic protein kinase Ciota signalling pathway for the treatment of cancer.
    Fields AP; Frederick LA; Regala RP
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):996-1000. PubMed ID: 17956262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells.
    Stallings-Mann M; Jamieson L; Regala RP; Weems C; Murray NR; Fields AP
    Cancer Res; 2006 Feb; 66(3):1767-74. PubMed ID: 16452237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinase C
    Kenchappa RS; Liu Y; Argenziano MG; Banu MA; Mladek AC; West R; Luu A; Quiñones-Hinojosa A; Hambardzumyan D; Justilien V; Leitges M; Sarkaria JN; Sims PA; Canoll P; Murray NR; Fields AP; Rosenfeld SS
    Cell Rep; 2021 Nov; 37(8):110054. PubMed ID: 34818553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PREX1 integrates G protein-coupled receptor and phosphoinositide 3-kinase signaling to promote glioblastoma invasion.
    Gont A; Daneshmand M; Woulfe J; Lavictoire SJ; Lorimer IA
    Oncotarget; 2017 Jan; 8(5):8559-8573. PubMed ID: 28051998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PKC eta as a therapeutic target in glioblastoma multiforme.
    Martin PM; Hussaini IM
    Expert Opin Ther Targets; 2005 Apr; 9(2):299-313. PubMed ID: 15934917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of atypical protein kinase C‑ι effectively reduces the malignancy of prostate cancer cells by downregulating the NF-κB signaling cascade.
    Apostolatos AH; Ratnayake WS; Win-Piazza H; Apostolatos CA; Smalley T; Kang L; Salup R; Hill R; Acevedo-Duncan M
    Int J Oncol; 2018 Nov; 53(5):1836-1846. PubMed ID: 30226591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repression of cancer cell senescence by PKCι.
    Paget JA; Restall IJ; Daneshmand M; Mersereau JA; Simard MA; Parolin DA; Lavictoire SJ; Amin MS; Islam S; Lorimer IA
    Oncogene; 2012 Aug; 31(31):3584-96. PubMed ID: 22120720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein kinase C as a target for cancer therapy.
    Glazer RI
    Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):235-8. PubMed ID: 9212917
    [No Abstract]   [Full Text] [Related]  

  • 15. EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.
    Westphal M; Maire CL; Lamszus K
    CNS Drugs; 2017 Sep; 31(9):723-735. PubMed ID: 28791656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion.
    Butler AM; Scotti Buzhardt ML; Erdogan E; Li S; Inman KS; Fields AP; Murray NR
    Oncotarget; 2015 Jun; 6(17):15297-310. PubMed ID: 25915428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical protein kinase Cι (PKCι) promotes metastasis of esophageal squamous cell carcinoma by enhancing resistance to Anoikis via PKCι-SKP2-AKT pathway.
    Liu SG; Wang BS; Jiang YY; Zhang TT; Shi ZZ; Yang Y; Yang YL; Wang XC; Lin DC; Zhang Y; Yang H; Cai Y; Zhan QM; Wang MR
    Mol Cancer Res; 2011 Apr; 9(4):390-402. PubMed ID: 21310827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein kinase Cι expression and oncogenic signaling mechanisms in cancer.
    Murray NR; Kalari KR; Fields AP
    J Cell Physiol; 2011 Apr; 226(4):879-87. PubMed ID: 20945390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of glioblastoma cell invasion by PKC iota and RhoB.
    Baldwin RM; Parolin DA; Lorimer IA
    Oncogene; 2008 Jun; 27(25):3587-95. PubMed ID: 18212741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial: targeted therapy for glioblastoma multiforme.
    Halatsch ME
    Anticancer Agents Med Chem; 2011 Oct; 11(8):692. PubMed ID: 21864239
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.